NO20051477L - 2-tio-substituerte imidazolderivater og anvendelse av disse innen farmasi - Google Patents

2-tio-substituerte imidazolderivater og anvendelse av disse innen farmasi

Info

Publication number
NO20051477L
NO20051477L NO20051477A NO20051477A NO20051477L NO 20051477 L NO20051477 L NO 20051477L NO 20051477 A NO20051477 A NO 20051477A NO 20051477 A NO20051477 A NO 20051477A NO 20051477 L NO20051477 L NO 20051477L
Authority
NO
Norway
Prior art keywords
imidazole derivatives
thio
pharmaceuticals
substituted imidazole
thiosubstituted
Prior art date
Application number
NO20051477A
Other languages
English (en)
Norwegian (no)
Inventor
Stefan Laufer
Hans-Guenter Striegel
Karola Tollmann
Wolfgang Albrecht
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Publication of NO20051477L publication Critical patent/NO20051477L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
NO20051477A 2002-08-20 2005-03-18 2-tio-substituerte imidazolderivater og anvendelse av disse innen farmasi NO20051477L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10238045A DE10238045A1 (de) 2002-08-20 2002-08-20 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
PCT/EP2003/009219 WO2004018458A1 (fr) 2002-08-20 2003-08-20 Derives d'imidazol 2-thio-substitues et leur utilisation dans le domaine pharmaceutique

Publications (1)

Publication Number Publication Date
NO20051477L true NO20051477L (no) 2005-05-19

Family

ID=31197117

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051477A NO20051477L (no) 2002-08-20 2005-03-18 2-tio-substituerte imidazolderivater og anvendelse av disse innen farmasi

Country Status (19)

Country Link
US (1) US7582660B2 (fr)
EP (1) EP1539741A1 (fr)
JP (1) JP2005539035A (fr)
KR (1) KR20050058419A (fr)
CN (1) CN100396677C (fr)
AU (1) AU2003267000B2 (fr)
BR (1) BR0313277A (fr)
CA (1) CA2501849A1 (fr)
DE (1) DE10238045A1 (fr)
HR (1) HRP20050239A2 (fr)
IS (1) IS7740A (fr)
MX (1) MXPA05001985A (fr)
NO (1) NO20051477L (fr)
PL (1) PL375793A1 (fr)
RS (1) RS20050131A (fr)
RU (1) RU2331638C2 (fr)
UA (1) UA80718C2 (fr)
WO (1) WO2004018458A1 (fr)
ZA (1) ZA200501455B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2599449A1 (fr) * 2005-02-28 2006-08-31 Merckle Gmbh Derives d'imidazole de 2-sulfinyle et de 2-sulfonyle et leur utilisation comme inhibiteurs de cytokines
EP1894925A1 (fr) * 2006-08-24 2008-03-05 Merckle Gmbh Derivés d'imidazole ayant une activité anti-inflammatoire
US8143294B2 (en) * 2007-12-31 2012-03-27 Michael Burnet 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors
JP5912946B2 (ja) * 2012-01-11 2016-04-27 株式会社Adeka 感光性樹脂組成物
WO2022067063A1 (fr) * 2020-09-25 2022-03-31 Dana-Farber Cancer Institute, Inc. Inhibiteurs sélectifs d'egfr mutants et leurs méthodes d'utilisation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190666A (en) 1975-08-11 1980-02-26 E. I. Du Pont De Nemours And Company Anti-inflammatory 4,5-diarly-2-(substituted-thio)imidazoles and their corresponding sulfoxides and sulfones
EP0004648B1 (fr) * 1978-04-11 1982-08-25 Ciba-Geigy Ag Dérivés de mercapto-imidazole, procédé pour leur préparation, dérivés de mercapto-imidazole pour le traitement de maladies inflammatoires et leurs compositions pharmaceutiques
DE2823197A1 (de) 1978-05-24 1979-11-29 Schering Ag Neue imidazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3025484A1 (de) 1980-07-03 1982-02-04 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue imidazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3141063A1 (de) 1981-10-13 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue imidazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3504678A1 (de) 1985-02-12 1986-08-14 A. Nattermann & Cie GmbH, 5000 Köln Neue imidazolyl-oxyalkansaeuren und -thioalkansaeuren, ihre derivate und verfahren zu ihrer herstellung
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
SU1415725A1 (ru) 1986-11-17 1996-10-10 В.М. Виноградов Дигидрохлорид 4-(4'-метоксифенил)-2-морфолиноэтилтио-5-фенилимидазола, повышающий физическую выносливость
JPS6440467A (en) 1987-08-04 1989-02-10 Hisamitsu Pharmaceutical Co Novel substituted diphenylimidazole derivative
CA2003283A1 (fr) 1988-12-05 1990-06-05 C. Anne Higley Imidazoles pour le traitement de l'atherosclerose
MX9203711A (es) 1990-01-12 1992-07-01 Rhone Poulenc Rorer Sa Derivados de imidazol y composiciones farmaceuticas que los contienen.
GB9005966D0 (en) 1990-03-16 1990-05-09 May & Baker Ltd New compositions of matter
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5364875A (en) 1992-05-11 1994-11-15 The Du Pont Merck Pharmaceutical Company Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
CA2295021A1 (fr) * 1997-06-30 1999-01-28 Ortho-Mcneil Pharmaceutical, Inc. Imidazoles substituees en 2 utilisables pour le traitement de maladies inflammatoires
DE19842833B4 (de) * 1998-09-18 2005-04-14 Merckle Gmbh 2-Arylalkylthio-imidazole, 2-Arylalkenylthio-imidazole und 2-Arylalkinylthio-imidazole als Entzündungs-Hemmstoffe und Hemmstoffe der Cytokin-Freisetzung
DE10107683A1 (de) 2001-02-19 2002-08-29 Merckle Gmbh Chem Pharm Fabrik 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
DE10114775A1 (de) 2001-03-26 2002-10-10 Gerhard Dannhardt 2-Mercapto-4,5-diarylimidazolderivate und ihre Verwendung in der Pharmazie
DE10222103A1 (de) 2002-05-17 2003-11-27 Merckle Gmbh Chem Pharm Fabrik 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie

Also Published As

Publication number Publication date
KR20050058419A (ko) 2005-06-16
EP1539741A1 (fr) 2005-06-15
DE10238045A1 (de) 2004-03-04
HRP20050239A2 (en) 2005-10-31
ZA200501455B (en) 2006-10-25
WO2004018458A1 (fr) 2004-03-04
US7582660B2 (en) 2009-09-01
RU2005107726A (ru) 2006-01-20
UA80718C2 (en) 2007-10-25
IS7740A (is) 2005-03-14
MXPA05001985A (es) 2005-05-27
CN1675197A (zh) 2005-09-28
RS20050131A (sr) 2007-06-04
JP2005539035A (ja) 2005-12-22
RU2331638C2 (ru) 2008-08-20
CA2501849A1 (fr) 2004-03-04
AU2003267000B2 (en) 2009-05-28
AU2003267000A1 (en) 2004-03-11
CN100396677C (zh) 2008-06-25
US20060235054A1 (en) 2006-10-19
BR0313277A (pt) 2005-06-21
PL375793A1 (en) 2005-12-12

Similar Documents

Publication Publication Date Title
NO20082414L (no) Inhibitorer av AKT-aktivitet
BRPI0412993A (pt) inibidores da atividade da akt
NO20060717L (no) Sykliske derivater som modulatorer av kjemokin reseptoractivitet
NL1025067A1 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
NO20054414L (no) Dihydropteridinoner, metoder for deres fremstilling og bruk av disse som medisiner
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
ATE305448T1 (de) Phenylalaninderivate als herbizide
NO20050007L (no) 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander
NO20066055L (no) Pyridinderivater
WO2005123731A3 (fr) Composes organiques
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
DE60315677D1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
ATE313532T1 (de) Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
NO20061656L (no) 2,4 di(hetero)-arylamino-pyrimidin derivaer som ZAP-70 og/aller SYK inhibitorer
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
GB0130341D0 (en) Compounds
NO20054905D0 (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20070726L (no) Koblede pyrimidoner anvendbare i behandling eller forebygging av kreft
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20074912L (no) 2-sulfinyl- og 2-sulfonyl-substituerte imidazolderivater og anvendelse derav som cytokininhibitorer
WO2002060374A3 (fr) Derives de benz-1,3-azole et leurs utilisations en tant qu'inhibiteurs de l'heparanase
NO20063062L (no) Imidazolderivater, fremgangsmate for fremstilling og anvendelse av disse
TW200635921A (en) Organic compounds
MX2007004738A (es) Inhibidores de mif.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application